Tislelizumab

Leap Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Friday, May 13, 2022
Company, Risk, Private Securities Litigation Reform Act, Research, Docetaxel, Survival, EDGAR, Nasdaq, Medicare Part D, Progression-free survival, Patient, Tislelizumab, Therapy, ORR, Clinical trial, Stomach, COVID-19, Myeloid-derived suppressor cell, Great Leap Forward, Cancer, Prostate cancer, Companion diagnostic, PFS, Securities Exchange Act of 1934, Securities Act of 1933, DKK1, NK, NYU Langone Health, ASCO, Drug Quality and Security Act, Leica Biosystems, Leica, Distinguishing, Growth, Outline, Annual report, Pharmaceutical industry, Medical imaging, Cryptocurrency, Part, LEAP, BeiGene, New York University

CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.

Key Points: 
  • CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.
  • Net Loss was$10.4 millionfor the first quarter 2022, compared to$9.1 millionfor the same period in 2021.
  • Research and development expenses were $7.8 millionfor the first quarter 2022, compared to$6.8 millionfor the same period in 2021.
  • General and administrative expenses were$2.8 millionfor the first quarter 2022, compared to$2.7 millionfor the same period in 2021.

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

Retrieved on: 
Thursday, May 12, 2022
Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, Data analysis, BTK, Disease, Lymphoid leukemia, Company, Private Securities Litigation Reform Act, Food, U.S. Securities and Exchange Commission, Jazz Pharmaceuticals, Mantle cell lymphoma, Patient, Goal, Tislelizumab, Data set, Review, Pharmacokinetics, Half-life, PARP, COVID-19, Marketing, Bristol Myers Squibb, Novartis, Form 10-Q, BLA, Research, FDA, Global health, Food and Drug Administration, Intellectual property, Safety, Union, Technology, Therapy, Twitter, Tissue, Pharmaceutical industry, BeiGene, EU

BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets.

Key Points: 
  • BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets.
  • Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions.
  • BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs.
  • Novartis and BeiGene also entered into a strategic commercial agreement through which BeiGene will promote five approved Novartis Oncology products across designated regions of China.

Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Hope, COVID-19, ASCO, Drug development, U.S. Securities and Exchange Commission, Forward-looking statement, ADC, Investment, Quarter, World, Twitter, Inc., SVP, Tislelizumab, Company, NYSE, Engineering, Safety, Research, Time, Poster, BTC, Patient, Security (finance), Clinical trial, Program, Conjugation, GEA, Workforce, Cost sharing, PD-1, Private Securities Litigation Reform Act, Investigational New Drug, London, CEO, Technology, Zymeworks, HER2, Fine chemical, Medicine, Pharmaceutical industry, Online gambling, BeiGene

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2022.
  • The technology licensing agreement with Atreca provides further validation of our auristatin-based ADC and technology platforms and showcases our ability to generate continued non-dilutive funding opportunities.
  • As of March 31, 2022, Zymeworks had $300.5 million in cash resources consisting of cash, cash equivalents and short-term investments.
  • Zymeworks cannot guarantee future results, events, levels of activity, performance or achievements.

BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey

Retrieved on: 
Friday, April 29, 2022
Science, Biotechnology, Research, Pharmaceutical, Other Manufacturing, Oncology, Health, Manufacturing, DPR Construction, Global health, Entrepreneurship, U.S. Securities and Exchange Commission, CEO, LLC, Patient, Twitter, Annual report, FDA, Novartis, DPR, Private Securities Litigation Reform Act, COVID-19, Cancer, Technology, Growth, Jazz Pharmaceuticals, Company, BTK, Therapy, Goal, Intellectual property, BLA, Hopewell Township, Marketing, Ethics, Research, SSE, Engineering, PARP, NASDAQ, Bristol Myers Squibb, Tislelizumab, Form 10-K, Safety, Pharmaceutical industry, BeiGene, EU

BeiGene intends to recruit hundreds of new hires from the areas attractive talent market to support its continued growth and its commitment to producing life-saving oncology medicines.

Key Points: 
  • BeiGene intends to recruit hundreds of new hires from the areas attractive talent market to support its continued growth and its commitment to producing life-saving oncology medicines.
  • We are proud to welcome BeiGene to the Princeton area and look forward to the company manufacturing innovative cancer medicines in its new state-of-the-art facility.
  • We look forward to continuing to work with BeiGene and are excited about what will be produced here in Hopewell.
  • Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions.

Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Docetaxel, PD-1, Inc., HER2, Zymeworks, ASCO, U.S. Securities and Exchange Commission, NYSE, CAPOX, Conjugation, Patient, Twitter, COVID-19, Forward-looking statement, GEA, 2021 Essex County Council election, Annual report, Private Securities Litigation Reform Act, Security (finance), News, Drug development, Research, Engineering, Tislelizumab, Safety, Pharmaceutical industry, BeiGene

The presentations will provide new clinical data from two early-stage studies of zanidatamab in first-line oncology settings.

Key Points: 
  • The presentations will provide new clinical data from two early-stage studies of zanidatamab in first-line oncology settings.
  • This is the first clinical data presentation of zanidatamab in combination with chemotherapy and a PD-1 inhibitor.
  • This will be the first clinical data presentation of zanidatamab in a first-line setting of advanced/metastatic HER2-positive breast cancer.
  • The poster presentations will be available on their respective presentation dates on the conference website as well as the Zymeworks website.

BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 27, 2022
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Jazz Pharmaceuticals, COVID-19, NMPA, Research, PD-1, Patient, PARP, Review, Technology, National Medical Products Administration, Large-cell lung carcinoma, Antibody, FDA, Annual report, ESCC, DNA, U.S. Securities and Exchange Commission, Food, Private Securities Litigation Reform Act, Company, Tislelizumab, Disease, Macrophage, Pharmacokinetics, Marketing, Twitter, Half-life, HCC, Novartis, Lymphoid leukemia, Goal, Tissue, Intellectual property, NSCLC, Food and Drug Administration, Safety, BLA, Therapy, MSI, BTK, Squamous cell carcinoma, Hepatitis B virus, HBV, TIS, Form 10-K, Global health, Bristol Myers Squibb, Union, Hematological Cancer Research Investment and Education Act, Vaccine, Pharmaceutical industry, EU, BeiGene

BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets.

Key Points: 
  • BRUKINSA is supported by a broad clinical program which includes more than 3,900 subjects in 35 trials across 28 markets.
  • In January 2021, BeiGene partnered with Novartis to accelerate the clinical development and marketing of tislelizumab in the U.S., Europe, and Japan.
  • Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions.
  • Novartis and BeiGene also entered into a strategic commercial agreement through which BeiGene will promote five approved Novartis Oncology products across designated regions of China.

Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene

Retrieved on: 
Monday, April 25, 2022
Drug development, CEO, BTK, Bispecific monoclonal antibody, Monoclonal antibody, Twitter, Research, NASDAQ, Patient, Efficiency, PARP, Amblyomma integrum, Technology, Proteolysis, Tislelizumab, Chimera, CDAC, Mouse, SSE, ADC, Senior, Therapy, Cancer, Vaccine, EU, BeiGene

BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

Key Points: 
  • BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.
  • RenMaband RenLitemice, which have proprietary intellectual property rights, were developed by Biocytogen over the course of 5 years using size-unlimited, precise chromosome engineering technology.
  • BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.
  • Dr. Lai Wang, Senior Vice President and Global Head of R&D of BeiGene, said, "BeiGene has always been focused on developing differentiated innovative drugs and the application of innovative technologies.

Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene

Retrieved on: 
Monday, April 25, 2022
Drug development, CEO, BTK, Bispecific monoclonal antibody, Monoclonal antibody, Twitter, Research, NASDAQ, Patient, Efficiency, PARP, Amblyomma integrum, Technology, Proteolysis, Tislelizumab, Chimera, CDAC, Mouse, Multimedia, SSE, ADC, Senior, View, Therapy, Cancer, Vaccine, EU, BeiGene

BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.

Key Points: 
  • BEIJING, April 25, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen's fully human antibody RenMab/RenLitemice platforms to develop fully human monoclonal antibodies, bispecific antibodies and other types of antibody drugs.
  • RenMaband RenLitemice, which have proprietary intellectual property rights, were developed by Biocytogen over the course of 5 years using size-unlimited, precise chromosome engineering technology.
  • BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.
  • Dr. Lai Wang, Senior Vice President and Global Head of R&D of BeiGene, said, "BeiGene has always been focused on developing differentiated innovative drugs and the application of innovative technologies.

BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, BLA, Private Securities Litigation Reform Act, Company, Form 10-K, Therapy, PARP, Marketing, Annual report, Global health, Research, Jazz Pharmaceuticals, National Medical Products Administration, Novartis, NMPA, PD-1, Safety, Technology, Twitter, U.S. Securities and Exchange Commission, Macrophage, Hematological Cancer Research Investment and Education Act, Goal, COVID-19, BTK, Intellectual property, Bristol Myers Squibb, FDA, ESCC, Patient, Large-cell lung carcinoma, Antibody, Pharmaceutical industry, Tislelizumab, NSCLC, EU, BeiGene

BeiGene has initiated or completed more than 20 potentially registration-enabling clinical trials in 35 countries and regions, including 17 Phase 3 trials and four pivotal Phase 2 trials.

Key Points: 
  • BeiGene has initiated or completed more than 20 potentially registration-enabling clinical trials in 35 countries and regions, including 17 Phase 3 trials and four pivotal Phase 2 trials.
  • Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment in seven indications, including multiple approvals in NSCLC.
  • In January 2021, BeiGene partnered with Novartis to accelerate the clinical development and marketing of tislelizumab in the US, EU and Japan.
  • Our expansive portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions.

China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-High or Mismatch Repair-Deficient Solid Tumors

Retrieved on: 
Friday, March 11, 2022
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Microsatellite Instability-High or Mismatch Repair Deficient Solid Tumors, Tislelizumab, the Tislelizumab Clinical Program, BeiGene, MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT SOLID TUMORS, TISLELIZUMAB, THE TISLELIZUMAB CLINICAL PROGRAM, BEIGENE

Results from the clinical trial of tislelizumab in patients with MSI-H and dMMR solid tumors demonstrated that tislelizumabs treatment effect was consistent and durable across tumor types and endpoints.

Key Points: 
  • Results from the clinical trial of tislelizumab in patients with MSI-H and dMMR solid tumors demonstrated that tislelizumabs treatment effect was consistent and durable across tumor types and endpoints.
  • Todays approval is a great step for patients in China with MSI-H and dMMR solid tumors.
  • The NMPAs approval of tislelizumab is welcoming news to patients with MSI-H and dMMR solid tumors, which are particularly prevalent among the many patients with cancers of the gastrointestinal tract.
  • We are pleased to have a tissue-agnostic treatment approach with tislelizumab now available to those patients in need.